

1 **Abstract**

2

3 Pathogen populations can evolve in response to selective pressure from vaccine-induced immune
4 responses. For HIV, models predict that viral adaptation, either via strain replacement or selection
5 on *de novo* mutation, may rapidly reduce the effectiveness of an HIV vaccine. We hypothesized
6 that behavioral risk compensation after vaccination may accelerate the transmission of vaccine
7 resistant strains, increasing the rate of viral adaptation and leading to a more rapid decline in
8 vaccine effectiveness. To test our hypothesis, we modeled: a) the impact of risk compensation
9 on rates of HIV adaptation via strain replacement in response to a partially effective vaccine; and
10 b) the combined impact of risk compensation and viral adaptation on vaccine-mediated epidemic
11 control. We used an agent-based epidemic model that was calibrated to HIV-1 trends in South
12 Africa, and includes demographics, sexual network structure and behavior, and within-host
13 disease dynamics. Our model predicts that risk compensation can increase the rate of HIV viral
14 adaptation in response to a vaccine. In combination, risk compensation and viral adaptation can,
15 under certain scenarios, reverse initial declines in prevalence due to vaccination, and result in
16 HIV prevalence at 15 years equal to or greater than prevalence without a vaccine.

17

18 **Introduction**

19 Recent years have seen increased availability of effective biomedical HIV-1 prevention
20 tools, including the provision of antiretroviral therapy (ART) for prevention and pre-exposure
21 prophylaxis (PrEP). However, challenges in ART coverage and uptake of PrEP indicate that an
22 HIV-1 vaccine will be a necessary addition to combination prevention for epidemic control.¹ To
23 date, one HIV-1 vaccine trial (RV144) has shown modest efficacy, reducing the risk of HIV-1
24 infection by 31% at 3.5 years after vaccination.² However, post-hoc sieve analyses³ showed that
25 the vaccine was differentially efficacious against viral genotypes, with efficacy ranging from 40%
26 to 80% against three viral genotypes and a non-significant effect against others.⁴ These results

1 suggest that the observed 31% vaccine efficacy (reduction in overall rate of infection) was an
2 aggregate over viral genotypes present in the population; i.e., this population level vaccine
3 efficacy estimate is an average of strain-specific efficacies, weighted by strain population
4 frequency. Our previous work predicted that HIV-1 viral diversity may lead to viral adaptation in
5 response to a partially effective leaky vaccine, reducing vaccine effectiveness at the population
6 level over time as resistant strains rise in frequency.⁵ This process of vaccine-induced viral
7 adaptation (via strain replacement) has been empirically observed in other pathogens, including
8 *Streptococcus pneumoniae*, *Haemophilus influenzae*, and others.^{6,7}

9 Risk compensation may pose an additional threat to population-level impact of a partially
10 effective vaccine.⁸ Risk homeostasis theory posits that each individual has a unique risk set point,
11 with the consequence that reductions in risk achieved by one preventive therapy or behavior will
12 be offset by increases in risk through compensatory changes in behavior to maintain an
13 equilibrium risk level.⁹ In a study of HIV vaccine attitudes among high-risk adults in Los Angeles,
14 10% of respondents indicated they would reduce condom use if they were vaccinated, and this
15 risk compensation was positively associated with perceived acceptability of a potential
16 vaccine.^{10,11} In another study of vaccine acceptability and risk compensation among high-risk
17 MSM and transgender people in Thailand, over one-third of participants reported intentions to
18 increase post-vaccination risk behaviors.¹² In a network-based health decision model of
19 vaccination for HIV in a theoretical population, unprotected sex increased after vaccination.¹³
20 Observational studies of risk compensation for human vaccines that have already been
21 introduced are mixed: no increases in high risk behavior were identified among HPV vaccinated
22 individuals (reviewed in Brewer¹⁴).

23 Observational data from other HIV prevention measures suggest that risk compensation
24 may occur with a preventative HIV vaccine: as PrEP has become widely available, evidence from
25 demonstration projects and implementation settings in high-income countries has shown an
26 increase in condom-less anal sex among PrEP users,¹⁵⁻¹⁸ although no increase in the number of

1 sexual partners has been observed.^{17,18} An increase in incidence of sexually transmitted infections
2 among PrEP users relative to non-users also provides indirect evidence of risk compensation.^{19,20}
3 This might not apply generally, as no evidence of risk compensation following PrEP initiation was
4 seen for heterosexual HIV serodiscordant couples in Kenya and Uganda.²¹ Evidence from sub-
5 Saharan African settings of risk compensation in response to rollout of voluntary medical male
6 circumcision is also mixed, with two of three of the randomized clinical trials finding evidence of
7 small increases in condom-related and sexual contact frequency risk behaviors,²²⁻²⁴ but not with
8 respect to number of partners, and recent evidence following rollout has not identified significant
9 increases in risk behaviors among circumcised men.²⁵⁻²⁹ An observational study in Kenya
10 estimated that men undergoing voluntary medical circumcision were 42% more likely to report
11 two or more sexual partners in the previous year.³⁰

12 Previous mathematical modeling of partially effective HIV-1 vaccines similar to that tested
13 in RV144 has predicted that a vaccine with 60% coverage will avert 6-15% of infections over 10
14 years,³¹⁻³³ with greater gains achieved with continuous coverage and regular booster vaccination.
15 A review of models using similar methods to assess the cost-effectiveness of a partially effective
16 HIV-1 vaccine concluded that an HIV-1 vaccine would be a cost-effective prevention strategy
17 under the majority of conditions and assumptions, with potential cost savings with targeted
18 vaccination strategies.^{33,34}

19 However, these analyses have largely overlooked the mitigating factors of viral adaptation
20 and risk compensation, and none have modeled both factors simultaneously. Previous models
21 have predicted a limited effect of risk compensation on vaccine impact, with large reductions in
22 incidence even in the presence of increases in risky behavior among vaccinated
23 individuals.^{31,32,35,36} Yet increased risk behavior by vaccinated individuals, under the assumption
24 of protection, may result in more frequent transmission of resistant viruses and lead to the faster
25 spread of vaccine resistance and a more rapid decline in vaccine effectiveness.

1 Here we evaluate the potential combined effect of risk compensation and viral adaptation
2 through epidemic and evolutionary modeling of an HIV-1 vaccine implemented in South Africa.
3 We hypothesize that risk compensation will accelerate rates of viral adaptation, resulting in a
4 larger detrimental impact on vaccine effectiveness than viral adaptation and risk compensation
5 operating alone. We further hypothesize that viral adaptation and risk compensation will reduce
6 the cost-effectiveness of a vaccine.

7

8 **Results**

9 Using a stochastic, agent-based HIV-1 epidemic model calibrated to South Africa, we
10 modeled: 1) the impact of behavioral risk compensation on rates of viral population-level
11 adaptation in response to vaccination; and 2) the combined effects of risk compensation and viral
12 adaptation on vaccine-mediated epidemic control. We also calculated the cost-effectiveness of a
13 partially effective HIV vaccine accounting for viral adaptation and risk compensation.

14 In the absence of both vaccine-resistant viral strains and risk compensation, our baseline
15 model scenario predicts that an HIV-1 vaccine with 50% efficacy implemented with 70% coverage
16 may result in an HIV-1 prevalence of 7.8% (95% CrI: 7.0, 8.4), following 15 years of continuous
17 vaccination, compared to prevalence of 13.6% (95% CrI: 12.5, 14.9) in a counterfactual scenario
18 without a vaccine ([Figure 1; Table S1](#)). This decline in prevalence reflects 56.8% (95% CrI: 41.4,
19 69.0) of infections averted over that time span (compared to the counterfactual with no vaccine)
20 ([Figure 2; Table S2](#)).

21

22 *Impact of risk compensation on rates of HIV adaptation*

23 For the baseline scenario *with* viral adaptation (50% overall vaccine efficacy, 70% vaccine
24 coverage, and 17% of virus vaccine resistant at rollout) but in the absence of risk compensation,
25 our model predicts that the vaccine resistant allele frequency will increase over time after the
26 rollout of a partially effective vaccine: within 15 years the resistant allele frequency has increased

1 from 17% to ~45% (Figure 3). Likewise, during this time period the resistant allele incidence has
2 increased from ~0.4% to ~1.3% (Figure 4). In scenarios with higher initial frequencies of resistant
3 virus (i.e. 28.6%, 37.5%), the resistant virus frequency reaches ~60% and ~70% after 15 years,
4 respectively (Figure S3). With viral adaptation *and* risk compensation, HIV adaptation occurs
5 more rapidly. In the baseline model scenario with adaptation and risk compensation, within 15
6 years the resistant allele frequency has increased from 17% to ~55% and incidence has increased
7 from ~0.4% to ~2.4% (Figure S3).

8

9 *Combined impact of risk compensation and HIV adaptation on vaccine effectiveness*

10 With the baseline scenario and risk compensation alone (without vaccine-resistant viral
11 strains), the vaccine is predicted to result in decreased incidence and prevalence, and lead to
12 infections averted, yet with a weaker impact compared to the baseline scenario *without* risk
13 compensation (Figure 1, Figures S4, S5, S6). A 5% decrease in condom use among vaccinated
14 individuals results in 8.0% (95% CrI: 7.3, 8.7) prevalence at fifteen years after vaccine rollout,
15 while a 30% decrease in condom use among vaccinated individuals results in 9.3% prevalence
16 (95% CrI: 8.6, 10.2), both compared to a prevalence of 7.8 (95% CrI: 7.0, 8.4) without risk
17 compensation (reduced from 13.6% prevalence without vaccination). These scenarios result in
18 55.1% (95% CrI: 42.3, 69.6) and 41.6% (95% CrI: 29.3, 50.5) of infections averted, for 5% and
19 30% decreases in condom use, respectively, compared to 56.8% of infections averted with no
20 risk compensation (Table S2).

21 With only the presence of vaccine-resistant viral strains (without risk compensation), with
22 17% of virus vaccine resistant at rollout, viral population-level adaptation substantially reduces
23 vaccine impact: HIV prevalence is reduced to 10.4% (95% CrI: 8.3, 11.8) within 15 years after
24 vaccine rollout, compared to a reduction to 7.8% prevalence in the baseline scenario in which all
25 virus is vaccine sensitive (Figure 1, Table S1). Initial declines in prevalence are driven by rapid
26 decreases in incidence of vaccine-sensitive viral strains; the near elimination of vaccine-sensitive

1 viral infections is accompanied by an increase in the incidence of vaccine-resistant infections,
2 which represent the majority of incident viral strains within seven years of vaccine rollout ([Figure](#)
3 [4](#)). In the same comparison of scenarios, infections averted through vaccination (15 years after
4 rollout) declined from 56.8% averted in the baseline scenario *without* resistant virus to only 16.8%
5 averted (95% CrI: -4.4, 41.5) with 17% resistant virus at rollout ([Figure 2](#)). Most notable, HIV-1
6 prevalence following fifteen years of vaccination increases (prevalence range: 10.4%-11.8%) as
7 vaccine coverage and initial resistant virus frequency increase ([Figure 1, Table S1](#)).

8 The presence of *both* risk compensation and viral adaptation results in poorer epidemic
9 control than with either operating alone. As described above, compared to the baseline scenario,
10 risk compensation alone (via a 30% reduction in condom use among vaccinated individuals and
11 no viral adaptation) may reduce the vaccine impact on prevalence by 1.5 percentage points and
12 avert 17.2% fewer infections; viral adaptation alone (with no risk compensation) may reduce the
13 vaccine impact on prevalence by 2.6 percentage points and avert 40% fewer infections. Yet with
14 both risk compensation and viral adaptation, HIV prevalence is 5.8 percentage points higher than
15 in a scenario with neither risk compensation nor viral adaptation ([Figure 1, Table S1](#)), an absolute
16 difference of 1.8 percentage points above the simple additive effect of viral adaptation and risk
17 compensation. In this scenario, initial declines in prevalence are reversed at approximately 10
18 years following vaccine rollout, as the combination of risk compensation and viral adaptation result
19 in a rebound in prevalence such that following 15 years of vaccine implementation, prevalence is
20 13.6% (95% CrI: 11.7, 15.3), equal to prevalence in the absence of a vaccine ([Figure 1, Table](#)
21 [S1](#)). In six of nine epidemic scenarios evaluated, the synergistic effects of risk compensation and
22 viral adaptation led to worse epidemic outcomes than in the absence of a vaccine ([Figure 5,](#)
23 [Figure S4, S5, S6, Table S2](#)).

24

25 *Cost-effectiveness*

1 We estimated the incremental cost-effectiveness ratio (ICER) per infection averted for a
2 partially effective HIV vaccine in scenarios of viral adaptation and risk compensation. First, in the
3 absence of both vaccine-resistant viral strains and risk compensation, our baseline scenario of
4 an HIV-1 vaccine with 50% efficacy and 70% coverage predicts an ICER of \$157 per infection
5 averted (90% CrI: \$75, \$240) over 15 years of vaccination, compared to scenarios without a
6 vaccine (Table 1, Table S3). Second, while both viral adaptation alone and risk compensation
7 alone increase the ICER per infection averted of an HIV vaccine by approximately 3-fold (Table
8 1, Figure S7), the concurrent effects of viral adaptation and risk compensation can result in as
9 much as 24-fold reduced cost-effectiveness (e.g. ICER per infection averted of \$3,786, for
10 scenarios with 17% resistant virus at vaccine rollout and a 30% decrease in condom use in
11 vaccinated individuals). (We discuss the ICER estimates for DALYs in the Supporting
12 Information.)

13

14 **Discussion**

15 In our simulations of an HIV-1 vaccination program in South Africa, viral adaptation and
16 risk compensation independently and synergistically impacted vaccination campaigns to result in
17 substantially lower epidemic gains than predicted in counterfactual scenarios without these
18 factors. In some scenarios, the combination of viral adaptation and risk compensation resulted in
19 worse epidemic outcomes with a vaccine than without.

20 These results emphasize the importance of several aspects of vaccine implementation
21 and design. First, viral genomic sieve analyses from all current and future HIV-1 vaccine trials
22 should be conducted to identify viral strains that were differentially impacted by the vaccine.
23 Second, surveillance of HIV-1 diversity in a vaccinated population can inform the risk of viral
24 adaptation and the need for ongoing modification of a vaccine to include inserts (antigens) against
25 alternate viral strains.

1 Additional HIV-1 vaccine trials of a Mosaic vaccine are currently ongoing in North America,
2 South America, Africa, and Europe (HVTN 705/*Imbokodo* and HVTN 706/*Mosaico*). The Mosaic
3 vaccine is designed to be effective against multiple viral strains, with the expectation that this may
4 also limit rates of viral adaptation. It is possible that concurrent scale-up of additional HIV-1
5 prevention methods, such as PrEP, may decrease rates of viral evolution (by decreasing total
6 transmissions and rates of viral spread). Additional modeling may inform simultaneous
7 implementation strategies. Finally, communication strategies that balance emphasis of the
8 benefits of an HIV-1 vaccine with an understanding that it is only partially effective may reduce
9 risk compensation among vaccine recipients and the general population.

10 Viral evolution and risk compensation also independently and synergistically reduce the
11 cost-effectiveness of an HIV-1 vaccine, with their synergistic effects amplifying declines in cost-
12 effectiveness. Counterintuitively, vaccination programs appear cost-effective even in scenarios
13 where long-term epidemic outcomes are worse than in the absence of a vaccine program because
14 cost-effectiveness analyses weight proximal costs and health outcomes more heavily than distal
15 outcomes, emphasizing the need to consider both epidemic outcomes and cost-effectiveness
16 analyses in concert.

17 There are several limitations in the work presented here. First, we modeled equal fitness
18 in both vaccine-sensitive and vaccine-resistant strains, i.e. sensitive and resistant viruses were
19 not linked to different viral loads or transmissibility in unvaccinated individuals. If, alternately,
20 vaccine resistance was linked with lower intra-host viral loads, we would likely observe slower
21 rates of viral adaptation, as transmission of resistant viruses would be attenuated. Our assumption
22 of equal fitness is supported by the observation that breakthrough infections in RV144 were not
23 associated with decreased viral load or slower rates of HIV disease progression.² Second, our
24 model does not include *de novo* intra-host mutation of vaccine resistance. Previous research,
25 however, has shown that HIV-1 has evolved in response to immune selection pressure;³⁷⁻³⁹ if we
26 included *de novo* mutations in our model to allow escape from the vaccine-elicited immune

1 response, this would likely result in faster population-level viral adaptation. Finally, while there is
2 growing evidence for risk compensation in response to PrEP rollout in high-income settings,
3 evidence of risk compensation in response to biomedical interventions in sub-Saharan Africa is
4 limited to male circumcision in Ugandan and Kenyan populations, rather than the South African
5 population that we have modeled. Additionally, risk compensation may take other forms that are
6 not modeled here, including community-level risk compensation^{20,40,41} and increases in the
7 number of sexual partners. Surveillance of behavioral changes in response to scale up of
8 treatment-as-prevention and PrEP in sub-Saharan Africa might evaluate those forms of risk
9 compensation most relevant to an African context.

10 In all scenarios, vaccine introduction resulted in epidemic gains in the first five years of
11 rollout. This timeframe suggests there will be an opportunity to monitor and respond to population-
12 level changes in viral strain frequencies and strain-specific incidence. Doing so will require robust
13 surveillance systems with rapid feedback to vaccine design teams, ensuring that modifications to
14 the vaccine can be responsive to epidemic needs. In conclusion, both viral adaptation and risk
15 compensation independently reduce the effectiveness of an HIV-1 vaccine, with their synergistic
16 effects accelerating the timeline of these reductions. Effective implementation of a future HIV-1
17 vaccine will require robust viral genetic and behavioral surveillance to ensure continued
18 effectiveness.

19

20 **Methods**

21 *Mathematical model*

22 We used an individual-based stochastic network model (*EvoNetHIV*, available here:
23 github.com/EvoNetHIV, and described in detail in the [Supplementary Information](#))⁵ to simulate
24 large-scale vaccine campaigns in populations in which there is viral diversity with respect to
25 vaccine efficacy. The model was calibrated to historical trends in HIV-1 prevalence in South
26 Africa,⁴²⁻⁴⁵ and included demographics, sexual network structure, sexual behavior, and within-

1 host HIV viral dynamics (Figure S1). We modeled each scenario with an initial population of
2 30,000, running from 1990 to 2030 (Figure S2). We performed 64 replicate simulations for each
3 scenario. Primary results describe the mean and 95% credible interval of these 64 replicates.

4

5 *Vaccine characteristics and scenarios*

6 Because our model was calibrated to the HIV-1 epidemic in South Africa, we modeled an
7 HIV-1 subtype C vaccine with characteristics hypothesized to be similar to the vaccine used in
8 the HVTN 702 trial in South Africa.⁴⁶ The vaccine effect in HVTN 702 was expected to wane over
9 time, similar to waning efficacy observed in RV144,⁴⁷ and HVTN 702 was powered to detect a
10 minimum effect of 50% vaccine efficacy at two years following vaccination. We therefore modeled
11 a partially effective and leaky vaccine, with exponentially decaying (per exposure) vaccine efficacy
12 of the form $VE_t = VE_0 - (1 - e^{-0.000306e-4t})$, with vaccine efficacy duration of five years (VE =
13 vaccine efficacy; t = time in days since vaccination). We calculated the initial vaccine efficacy and
14 rate of waning such that the overall population vaccine efficacy at two years in all scenarios,
15 weighted by the proportion of sensitive virus, was equal to 50%. Vaccination in the model begins
16 in year 2018, with user-specified coverage achieved over a three-year period and maintained for
17 the duration of the simulation. Individuals who receive the vaccine and remain HIV-1-negative for
18 the duration of vaccine efficacy are revaccinated at five years. All simulations model 15 years of
19 continuous vaccination coverage.

20 We modeled viral diversity with respect to vaccine efficacy as two genotypes (i.e. one
21 locus with two alleles) that determine whether a vaccinated individual is conferred a degree of
22 protection or no protection against HIV-1 infection, given a sexual contact with an HIV-infected
23 individual. In our primary analysis we initialized standing viral diversity at vaccine rollout to include
24 17% vaccine-resistant virus (83% vaccine-sensitive) and compared this scenario to a
25 counterfactual in which 100% of virus is vaccine sensitive. We included additional scenarios in
26 which 29% and 37% of virus is vaccine-resistant at rollout as sensitivity analyses. We also

1 evaluated variation in vaccine coverage, assessing 70% coverage in our primary analyses and
2 50% and 90% coverage in sensitivity analyses.

3 Risk compensation in response to biomedical interventions has been observed to be as
4 high as a 75% increase in high-risk sexual behavior in high-income settings,^{16,48} though has been
5 lower where observed in sub-Saharan Africa, ranging from 12%²⁴ to 18%.²² Evaluations of risk
6 compensation have additionally focused primarily on condom use, and, though less frequently
7 assessed, have rarely found changes in the number of sexual partners.^{17,18,22} We therefore model
8 risk compensation as a relative reduction in the per-act probability of condom use among
9 vaccinated individuals, evaluating the range of 5%-30% reduction. Baseline per-act probabilities
10 of condom use increase over time according to nationally representative surveys in South Africa
11 from 2002-2012.⁴²⁻⁴⁵

12

13 *Estimation of vaccine cost-effectiveness*

14 We calculated the incremental cost-effectiveness ratio (ICER) for the vaccine program,
15 using two health outcomes: infections averted and disability-adjusted life years (DALY) averted.
16 To estimate DALYs, we tracked the number of person-years spent in the following categories: 1)
17 HIV-infected with CD4+ T cell count >350; 2) HIV-infected with CD4 count between 200 and 350;
18 3) HIV-infected with CD4 <200; and 4) HIV-infected and on ART. The number of person-years in
19 each category was then multiplied by the corresponding disability weight to calculate category-
20 specific DALYs.⁴⁹ These, along with years of life lost due to premature AIDS death, were then
21 summed to total DALYs and used in comparisons across scenarios. We used sex-specific life
22 expectancy estimates for the year 2017 in estimation of DALYs.⁵⁰ Estimates of cost-effectiveness
23 include the incremental cost of the vaccination program, assuming a cost of \$60 per vaccine
24 series, following other models of an HIV-1 vaccine in middle-income countries,³⁴ as well as HIV-
25 1 care and treatment costs averted by the vaccine program.⁵¹ Both costs and health outcomes
26 are discounted at an annual rate of 3%.⁵²

27

1 **References**

2

- 3 1 Fauci, A. S. An HIV Vaccine Is Essential for Ending the HIV/AIDS Pandemic. *Jama* **318**,
4 1535-1536, doi:10.1001/jama.2017.13505 (2017).
- 5 2 Rerks-Ngarm, S. *et al.* Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection
6 in Thailand. *The New England journal of medicine* **361**, 2209-2220,
7 doi:10.1056/NEJMoa0908492 (2009).
- 8 3 Edlefsen, P. T., Gilbert, P. B. & Rolland, M. Sieve analysis in HIV-1 vaccine efficacy
9 trials. *Current opinion in HIV and AIDS* **8**, 432-436,
10 doi:10.1097/COH.0b013e328362db2b (2013).
- 11 4 Rolland, M. *et al.* Increased HIV-1 vaccine efficacy against viruses with genetic
12 signatures in Env V2. *Nature* **490**, 417-420, doi:10.1038/nature11519 (2012).
- 13 5 Herbeck, J. T. *et al.* HIV population-level adaptation can rapidly diminish the impact of a
14 partially effective vaccine. *Vaccine* **36**, 514-520, doi:10.1016/j.vaccine.2017.12.004
15 (2018).
- 16 6 Martcheva, M., Bolker, B. M. & Holt, R. D. Vaccine-induced pathogen strain
17 replacement: what are the mechanisms? *J R Soc Interface* **5**, 3-13,
18 doi:10.1098/rsif.2007.0236 (2008).
- 19 7 Read, A. & Mackinnon, M. in *Evolution in Health and Disease, 2nd edition* (eds SC
20 Stearns & J Koella) pp. 139-152. (Oxford University Press, 2008).
- 21 8 Eaton, L. A. & Kalichman, S. Risk compensation in HIV prevention: implications for
22 vaccines, microbicides, and other biomedical HIV prevention technologies. *Current*
23 *HIV/AIDS reports* **4**, 165-172 (2007).
- 24 9 Wilde, G. J. S. *Target Risk: Dealing with the danger of death, disease, and damage in*
25 *everyday decisions.*, (PDE Publications, 1994).
- 26 10 Newman, P. A. *et al.* Preventive HIV vaccine acceptability and behavioral risk
27 compensation among a random sample of high-risk adults in Los Angeles (LA VOICES).
28 *Health Serv Res* **44**, 2167-2179, doi:10.1111/j.1475-6773.2009.01039.x (2009).
- 29 11 Lee, S. J., Newman, P. A., Duan, N. & Cunningham, W. E. Development of an HIV
30 vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable
31 populations: L.A. VOICES. *Vaccine* **32**, 5013-5018, doi:10.1016/j.vaccine.2014.07.018
32 (2014).
- 33 12 Newman, P. A., Rongprakhon, S., Tepjan, S. & Yim, S. Preventive HIV vaccine
34 acceptability and behavioral risk compensation among high-risk men who have sex with
35 men and transgenders in Thailand. *Vaccine* **28**, 958-964,
36 doi:10.1016/j.vaccine.2009.10.142 (2010).
- 37 13 Tully, S., Cojocar, M. & Bauch, C. T. Sexual behavior, risk perception, and HIV
38 transmission can respond to HIV antiviral drugs and vaccines through multiple pathways.
39 *Sci Rep* **5**, 15411, doi:10.1038/srep15411 (2015).
- 40 14 Brewer, N. T., Cuite, C. L., Herrington, J. E. & Weinstein, N. D. Risk compensation and
41 vaccination: can getting vaccinated cause people to engage in risky behaviors? *Ann*
42 *Behav Med* **34**, 95-99, doi:10.1007/BF02879925 (2007).
- 43 15 Grant, R. M. *et al.* Uptake of pre-exposure prophylaxis, sexual practices, and HIV
44 incidence in men and transgender women who have sex with men: a cohort study.
45 *Lancet Infectious Diseases* **14**, 820-829, doi:10.1016/s1473-3099(14)70847-3 (2014).
- 46 16 McCormack, S. *et al.* Pre-exposure prophylaxis to prevent the acquisition of HIV-1
47 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label
48 randomised trial. *Lancet* **387**, 53-60, doi:10.1016/s0140-6736(15)00056-2 (2016).

- 1 17 Lal, L. *et al.* Medication adherence, condom use and sexually transmitted infections in
2 Australian preexposure prophylaxis users. *AIDS (London, England)* **31**, 1709-1714,
3 doi:10.1097/qad.0000000000001519 (2017).
- 4 18 Hoornenborg, E. *et al.* Change in sexual risk behaviour after six months of pre-exposure
5 prophylaxis use: results from the Amsterdam PrEP demonstration project. *AIDS*
6 *(London, England)*, doi:10.1097/qad.0000000000001874 (2018).
- 7 19 Montañó, M. A. *et al.* in *International Union against STI World and European Congress*.
8 20 Jenness, S. M. *et al.* Individual HIV Risk versus Population Impact of Risk
9 Compensation after HIV Preexposure Prophylaxis Initiation among Men Who Have Sex
10 with Men. *PloS one* **12**, e0169484, doi:10.1371/journal.pone.0169484 (2017).
- 11 21 Ortblad, K. F. *et al.* No Evidence of Sexual Risk Compensation Following PrEP Initiation
12 Among Heterosexual HIV Serodiscordant Couples in Kenya and Uganda. *AIDS and*
13 *behavior* **24**, 1365-1375, doi:10.1007/s10461-019-02720-4 (2020).
- 14 22 Auvert, B. *et al.* Randomized, controlled intervention trial of male circumcision for
15 reduction of HIV infection risk: the ANRS 1265 Trial. *PLoS medicine* **2**, e298,
16 doi:10.1371/journal.pmed.0020298 (2005).
- 17 23 Gray, R. H. *et al.* Male circumcision for HIV prevention in men in Rakai, Uganda: a
18 randomised trial. *Lancet* **369**, 657-666, doi:10.1016/s0140-6736(07)60313-4 (2007).
- 19 24 Bailey, R. C. *et al.* Male circumcision for HIV prevention in young men in Kisumu, Kenya:
20 a randomised controlled trial. *Lancet* **369**, 643-656, doi:10.1016/s0140-6736(07)60312-2
21 (2007).
- 22 25 Ortblad, K. F. *et al.* Does Incident Circumcision Lead to Risk Compensation? Evidence
23 From a Population Cohort in KwaZulu-Natal, South Africa. *Journal of acquired immune*
24 *deficiency syndromes (1999)* **80**, 269-275, doi:10.1097/QAI.0000000000001912 (2019).
- 25 26 Agot, K. E. *et al.* Male circumcision in Siaya and Bondo Districts, Kenya: prospective
26 cohort study to assess behavioral disinhibition following circumcision. *Journal of*
27 *acquired immune deficiency syndromes (1999)* **44**, 66-70,
28 doi:10.1097/01.qai.0000242455.05274.20 (2007).
- 29 27 Shi, C. F., Li, M. & Dushoff, J. Evidence that promotion of male circumcision did not lead
30 to sexual risk compensation in prioritized Sub-Saharan countries. *PloS one* **12**,
31 e0175928, doi:10.1371/journal.pone.0175928 (2017).
- 32 28 Auvert, B. *et al.* Association of the ANRS-12126 male circumcision project with HIV
33 levels among men in a South African township: evaluation of effectiveness using cross-
34 sectional surveys. *PLoS medicine* **10**, e1001509, doi:10.1371/journal.pmed.1001509
35 (2013).
- 36 29 Gray, R. *et al.* The effectiveness of male circumcision for HIV prevention and effects on
37 risk behaviors in a posttrial follow-up study. *AIDS (London, England)* **26**, 609-615,
38 doi:10.1097/QAD.0b013e3283504a3f (2012).
- 39 30 Westercamp, M. *et al.* Changes in Male Circumcision Prevalence and Risk
40 Compensation in the Kisumu, Kenya Population, 2008-2013. *Journal of acquired*
41 *immune deficiency syndromes (1999)* **74**, e30-e37, doi:10.1097/qai.0000000000001180
42 (2017).
- 43 31 Hontelez, J. A. *et al.* The potential impact of RV144-like vaccines in rural South Africa: a
44 study using the STDSIM microsimulation model. *Vaccine* **29**, 6100-6106,
45 doi:10.1016/j.vaccine.2011.06.059 (2011).
- 46 32 Andersson, K. M., Paltiel, A. D. & Owens, D. K. The potential impact of an HIV vaccine
47 with rapidly waning protection on the epidemic in Southern Africa: examining the RV144
48 trial results. *Vaccine* **29**, 6107-6112, doi:10.1016/j.vaccine.2011.06.076 (2011).
- 49 33 Selinger, C. *et al.* Targeting and vaccine durability are key for population-level impact
50 and cost-effectiveness of a pox-protein HIV vaccine regimen in South Africa. *Vaccine* **37**,
51 2258-2267, doi:10.1016/j.vaccine.2019.02.073 (2019).

- 1 34 Adamson, B., Dimitrov, D., Devine, B. & Barnabas, R. The Potential Cost-Effectiveness
2 of HIV Vaccines: A Systematic Review. *PharmacoEconomics - open* **1**, 1-12,
3 doi:10.1007/s41669-016-0009-9 (2017).
- 4 35 Long, E. F. & Owens, D. K. The cost-effectiveness of a modestly effective HIV vaccine in
5 the United States. *Vaccine* **29**, 6113-6124, doi:10.1016/j.vaccine.2011.04.013 (2011).
- 6 36 Nagelkerke, N. J., Hontelez, J. A. & de Vlas, S. J. The potential impact of an HIV vaccine
7 with limited protection on HIV incidence in Thailand: a modeling study. *Vaccine* **29**,
8 6079-6085, doi:10.1016/j.vaccine.2011.06.048 (2011).
- 9 37 Cotton, L. A. *et al.* Genotypic and functional impact of HIV-1 adaptation to its host
10 population during the North American epidemic. *PLoS genetics* **10**, e1004295,
11 doi:10.1371/journal.pgen.1004295 (2014).
- 12 38 Schellens, I. M. *et al.* Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted
13 by protective HLA-B alleles during the HIV-1 epidemic. *AIDS (London, England)* **25**,
14 1691-1700, doi:10.1097/QAD.0b013e32834981b3 (2011).
- 15 39 Kawashima, Y. *et al.* Adaptation of HIV-1 to human leukocyte antigen class I. *Nature*
16 **458**, 641-645, doi:10.1038/nature07746 (2009).
- 17 40 Holt, M. & Murphy, D. A. Individual Versus Community-Level Risk Compensation
18 Following Preexposure Prophylaxis of HIV. *American journal of public health* **107**, 1568-
19 1571, doi:10.2105/ajph.2017.303930 (2017).
- 20 41 Young, A. M., Halgin, D. S., DiClemente, R. J., Sterk, C. E. & Havens, J. R. Will HIV
21 vaccination reshape HIV risk behavior networks? A social network analysis of drug
22 users' anticipated risk compensation. *PLoS one* **9**, e101047,
23 doi:10.1371/journal.pone.0101047 (2014).
- 24 42 Shisana, O. & Leickness, S. (Human Sciences Research Council Publishers, Cape
25 Town, South Africa, 2002).
- 26 43 Shisana, O. *et al.* (HSRC Press, Cape Town, 2005).
- 27 44 Shisana, O. *et al.* (HSRC Press, Cape Town, 2009).
- 28 45 Shisana, O. *et al.* (HSRC Press, Cape Town, 2014).
- 29 46 National Institutes of Health. *Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV*
30 *Vaccine Prevention Safety and Efficacy Study in South Africa (HVTN702)*,
31 <<https://clinicaltrials.gov/ct2/show/NCT02968849>> (2017).
- 32 47 Hankins, C. A., Glasser, J. W. & Chen, R. T. Modeling the impact of RV144-like vaccines
33 on HIV transmission. *Vaccine* **29**, 6069-6071, doi:10.1016/j.vaccine.2011.07.001 (2011).
- 34 48 Hughes, A. J., Chen, Y. H. & Scheer, S. Condomless Anal Sex Among HIV-Positive Men
35 Who Have Sex with Men: Biomedical Context Matters. *AIDS and behavior* **21**, 2886-
36 2894, doi:10.1007/s10461-017-1852-0 (2017).
- 37 49 Salomon, J. A. *et al.* Common values in assessing health outcomes from disease and
38 injury: disability weights measurement study for the Global Burden of Disease Study
39 2010. *Lancet* **380**, 2129-2143, doi:10.1016/S0140-6736(12)61680-8 (2012).
- 40 50 Statistics South Africa. (Pretoria, South Africa, 2017).
- 41 51 Meyer-Rath, G., Over, M., Klein, D. J. & Bershteyn, A. The Cost and Cost-Effectiveness
42 of Alternative Strategies to Expand Treatment to HIV-Positive South Africans: Scale
43 Economies and Outreach Costs. (Center for Global Development, Washington, DC,
44 2015).
- 45 52 World Health Organization. (World Health Organization, Geneva, Switzerland, 2003).

46

47

1 **Acknowledgements**

2 This work was supported by the U.S. National Institutes of Health grants R01-AI108490 (SMG,
3 JTH, JEM), R01-AI150467 (JTH), R21-HD075662 (SMG), R01-HD068395 (provided support to
4 SMG), and the University of Washington student technology fee (<https://uwstf.org>) (support for
5 the Hyak super-computer system used in this research). The funders had no role in study design,
6 data collection and analysis, decision to publish, or preparation of the manuscript.

7

8 **Author information**

9 *Affiliations*

10 Kathryn Peebles¹, John E. Mittler², Steven M. Goodreau^{3,4}, James T. Murphy⁵, Molly C. Reid¹,
11 Neil Abernethy^{6,7}, Geoffrey S. Gottlieb^{8,9}, Ruanne V. Barnabas^{1,5,8}, and Joshua T. Herbeck^{5,10}

12

13 ¹Department of Epidemiology, University of Washington, Seattle, WA

14 ²Department of Microbiology, University of Washington, Seattle, WA

15 ³Center for Studies in Demography and Ecology, University of Washington, Seattle, WA

16 ⁴Department of Anthropology, University of Washington, Seattle, WA

17 ⁵Department of Global Health, University of Washington, Seattle, WA

18 ⁶Department of Biomedical Inf. and Medical Education, University of Washington, Seattle, WA

19 ⁷Department of Health Services, University of Washington, Seattle, WA

20 ⁸Department of Medicine, University of Washington, Seattle, WA

21 ⁹Center for Emerging & Re-Emerging Infectious Diseases, University of Washington, Seattle,

22 WA

23 ¹⁰International Clinical Research Center, University of Washington, Seattle, WA

24

25 *Contributions*

1 K.P. and J.T.H. conceived and designed the study and drafted the manuscript. K.P. performed
2 the model analyses. K.P., J.E.M., S.M.G., J.T.M., M.C.R., N.A., G.S.G., and J.T.H. developed the
3 epidemiological and evolutionary model. K.P. and R.V.B. designed the cost effectiveness
4 analyses. All authors reviewed and interpreted the results and contributed to writing the final
5 manuscript.

6

7 *Corresponding author*

8 Correspondence to Joshua T. Herbeck, herbeck@uw.edu.

9


10 **Ethics declarations**

11 *Competing interests*

12 The authors declare no competing interests.

13

1




2

3 **Figure 1.** HIV-1 prevalence following introduction of a partially effective vaccine in the year 2018
4 (dashed vertical line), with 50% overall vaccine efficacy and 70% vaccine coverage. Model
5 scenarios shown include variation in the proportion of vaccine-sensitive virus at vaccine rollout
6 (83% or 100%) and variation in the reduction in condom use among vaccinated individuals (from
7 0% to 30% reduction). The mean and 95% credible interval of 64 replicates of each scenario are
8 shown. The black line shows the model scenario without a vaccine.

9

10




1

2 **Figure 2.** Percent of HIV-1 infections averted via vaccination over the first 15 years after vaccine
3 rollout, in model scenarios that include variation in the proportion of vaccine-sensitive virus at
4 vaccine rollout (83% or 100%) and variation in the reduction in condom use among vaccinated
5 individuals (from 0% to 30% reduction), with 50% overall vaccine efficacy and 70% vaccine
6 coverage.

7

8




1

2 **Figure 3.** Frequencies of HIV genotypes that are either sensitive or resistant to vaccine induced
3 immune responses, following introduction of a partially effective vaccine (here shown as years
4 from vaccine rollout). The plot shows the mean and 95% credible interval of 64 replicates for each
5 scenario (no vaccine, vaccine with risk compensation, and vaccine without risk compensation;
6 vaccine scenarios 83.3% vaccine sensitive virus at vaccine rollout and 70% population vaccine
7 coverage). Risk compensation is modeled as a 30% reduction in condom use among vaccinated
8 individuals.

9

10




1

2

3 **Figure 4.** HIV-1 incidence of vaccine-sensitive and vaccine-resistant viral strains following
4 introduction of a partially effective vaccine in the year 2018 (dashed vertical line), with 50% overall
5 vaccine efficacy and 70% vaccine coverage. Model scenarios include variation in the reduction in
6 condom use among vaccinated individuals (from 0% to 30% reduction). The mean and 95%
7 credible interval of 64 replicates of each scenario are shown. Black line shows total incidence
8 (incidence from sensitive and resistant viruses combined).

It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).



1

2 **Figure 5.** Heatmap of HIV-1 infections averted within 5, 10, and 15 years after vaccine rollout, for
3 multiple combinations of vaccine coverage, risk compensation in vaccinated individuals, and the
4 population frequency of the vaccine resistant virus, relative to a counterfactual model scenario
5 with no vaccine. Perverse vaccine outcomes can occur in scenarios with higher initial frequencies
6 of resistant virus and higher rates of risk compensation (decreased condom use), at all levels of
7 vaccine coverage.

8

1 **Table 1.** Incremental cost-effectiveness ratio (ICER) per infection averted and per DALY averted
 2 over 15 years of continuous vaccine implementation. Costs are in 2017 US dollars. The values in
 3 bold text represent the baseline scenario with vaccination, but without risk compensation or
 4 resistant virus.

Risk compensation	Percent sensitive virus at vaccine rollout							
	83%				100%			
	ICER (90% CrI) per infection averted				ICER (90% CrI) per DALY averted			
0%	\$528	(207, 1,054)	\$157	(75, 240)	\$161	(71, 400)	\$56	(28, 96)
5%	\$661	(344, 1,908)	\$181	(115, 291)	\$211	(116, 454)	\$69	(42, 114)
10%	\$1,091	(454, 2,669)	\$205	(108, 370)	\$296	(140, 617)	\$81	(41, 154)
15%	\$1,245	(413, 6,027)	\$257	(160, 434)	\$362	(139, 872)	\$107	(61, 177)
20%	\$2,144	(678, 7,150)	\$341	(203, 596)	\$457	(213, 1,272)	\$140	(65, 282)
25%	\$2,827	(* , 21,878)	\$396	(225, 620)	\$650	(249, 1,684)	\$156	(80, 295)
30%	\$3,786	(* , 96,644)	\$435	(243, 810)	\$726	(285, 2,700)	\$183	(90, 393)

6
 7
 8 *ICER is dominated (i.e., results in more infections in vaccine scenarios than in the absence of a
 9 vaccine).

10